Results 91 to 100 of about 18,115 (178)

Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?

, 2018
Gaurav Goel Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Abstract: Colorectal cancer (CRC) is a major public health problem in the United States with an estimated 50,260 deaths in 2017.
Goel G
core  

Combination treatments with regorafenib in preclinical models of colorectal cancer [PDF]

, 2020
Master i biomedisinIntroduction. Colorectal cancer (CRC) is the second most common cancer type in Norway in both genders. Active chemotherapy is used in first-line treatment regimens for patients with metastatic CRC (mCRC), which includes irinotecan and ...
Jørgensen, Suzanne Perregaard Munch
core  

Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China

BMC Cancer
Objective To evaluate the efficacy and safety of regorafenib monotherapy or in combination with immune-checkpoint inhibitor while treating Chinese patients with metastatic colorectal cancer (mCRC): a real-world study.
Wang Qu, Zimin Liu, Xiaobing Chen, Bo Liu, YunBo Zhao, Hao Yan, Xiujuan Qu, Shengmian Li, Aimin Zang, Yongkun Sun, Liangjun Zhu, Aiping Zhou   +11 more
doaj   +1 more source

Single dose regorafenib-induced hypertensive crisis

, 2014
Gastrointestinal stromal tumors (GISTs) are uncommon tumors of the gastrointestinal (GI) tract. Regorafenib is a new multikinase inhibitor and is approved for the treatment of GISTs in patients who develop resistance to imatinib and sunitinib.
Kemal, Y., Demirag, G., Kut, E., Teker, F., Yilmaz, B., Yucel, I.   +5 more
core  

Hepatosellülar karsinoma'da regorafenib etkilerinin incelenmesi

, 2017
Karaciğer kanseri dünya çapında en sık görülen beşinci kanser olup kansere bağlı ölümlerde ikinci sırada yer almaktadır. Uzun bir süre boyunca, Hepatosellüler Karsinoma (HCC)'nın tedavisinde FDA onaylı tek ilaç olarak bilinen Sorafenib'in, hasta ömrünü ...
MUSTAFA KARABİÇİCİ
core  

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice

Clinical and Translational Science, 2019
Regorafenib, a multikinase inhibitor used in the treatment of various solid tumors, undergoes extensive uridine 5′‐diphosphate glucuronosyltransferase (Ugt)1a9‐mediated glucuronidation to form regorafenib‐N‐β‐glucuronide (M7; RG), but the contribution of
Qiang Fu, Mingqing Chen, Jason T. Anderson, Xinxin Sun, Shuiying Hu, Alex Sparreboom, Sharyn D. Baker   +6 more
doaj   +1 more source

Gastrointestinale Stromatumoren: Regorafenib als Drittlinientherapie erfolgreich

, 2012
Eine potenzielle neue Standardtherapie für Patienten mit metastasiertem bzw. inoperablem GIST nach Imatinib-und Sunitinib-Versagen sieht Prof. Carsten Bokemeyer, Hamburg, in dem oralen Multikinase-Inhibitor Regorafenib.
Birgit Pohlmann
core   +1 more source

Early experience of seven hepatocellular carcinoma cases treated with regorafenib

Clinical Case Reports, 2018
Key Clinical Message Regorafenib became second‐line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects.
Shinsuke Uchikawa, Tomokazu Kawaoka, Hiroshi Aikata, Kenichiro Kodama, Yuki Inagaki, Masahiro Hatooka, Kei Morio, Takashi Nakahara, Eisuke Murakami, Akira Hiramatsu, Masataka Tsuge, Michio Imamura, Yoshiiku Kawakami, Kazuaki Chayama   +13 more
doaj   +1 more source

Effect of regorafenib on angiogenesis in neuroendocrine tumors in vitro.

, 2016
232 Background: Regorafenib, a potent multikinase inhibitor, targets a broad range of receptor tyrosine kinases (RTKs), including but not limited to VEGFR, PDGFR, and FGFR, which play an integral role in angiogenesis. Human neuroendocrine tumors (NETs)
Yi-Zarn Wang, Jennifer Owens, Eugene Woltering, Elise Juge, J Philip Boudreaux, Tanja Milosavljevic, Adrianne Reeks   +6 more
core   +1 more source

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice

, 2019
Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were ...
Hiroyuki Nakanishi, Leona Osawa, Yuka Hayakawa, Nobuyuki Enomoto, Nobuharu Tamaki, Koji Yamashita, Yuka Takahashi, Kaoru Tsuchiya, Mayu Higuchi, Jun Itakura, Namiki Izumi, Chiaki Maeyashiki, Masayuki Kurosaki, Sakura Kirino, Shun Kaneko, Yutaka Yasui, Kento Inada, Shuhei Sekiguchi, Wan Wang, Mao Okada, Kenta Takaura, Yasuhiro Asahina   +21 more
core   +1 more source